BRAF and melanoma: Although melanoma mortality has decreased in recent years owing largely to the introduction of immune checkpoint and BRAF/MEK kinase combination inhibition therapies as of 2018 [194], melanoma incidence has risen precipitously, particularly in regions with predominantly light-skinned populations, and survival with late-stage disease remains low [192,193,194,195].